Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality
Simon G Anderson, David C Hutchings, Mark Woodward, Kazem Rahimi, Martin K Rutter, Mike Kirby, Geoff Hackett, Andrew W Trafford, Adrian H Heald
Heart Nov 2016, 102 (21) 1750-1756; DOI: 10.1136/heartjnl-2015-309223